CEP-701: Began Phase II trials

Cephalon Inc. (CEPH), West Chester, Penn. Product: CEP-701 Business: Cancer Therapeutic category: Cell proliferation, Signal transduction Target: Tyrosine kinase receptors Description: Oral tyrosine ...